Securing PIPEs to Progress Fledgling Clinical Portfolios

Many of the small biotech companies that have listed on the public markets in the past few years have had to grapple with less-than-hoped-for IPO proceeds, low market valuations, and poor share liquidity. PIPE financings are allowing some of these companies to progress promising portfolios and offering investors potential upside on undervalued assets.

While in-licensing has jump-started Sunesis Pharmaceuticals Inc. 's discovery-stage pipeline and provided the assets necessary for the firm to go public in September 2005, like many of the small biotech companies that have listed on the public markets in the past few years, Sunesis has had to grapple with less-than-hoped-for IPO proceeds, a low market valuation, and poor share liquidity. [See Deal]

So far, so typical small-cap biotech. But as Sunesis' pipeline begins to mature—two in-licensed programs are entering Phase II studies...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo